Log In
Print
BCIQ
Print
Print this Print this
 

VK0612 (formerly MB07803)

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionFructose 1,6-bisphosphatase inhibitor
Molecular Target Fructose 1,6-bisphosphatase
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Viking Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today